How 17,000 AI-Certified Employees at AstraZeneca Are Helping It Achieve Its ‘Stretch Goal’ of $80 Billion in Revenue

(SeaPRwire) –   AstraZeneca has moved its AI strategy beyond the experimental phase, making employee upskilling a top priority.

The biopharmaceutical leader has now certified over 17,000 staff members in AI skills, according to CFO Aradhana Sarin. The initiative mandates that all employees above a specific level achieve at least a silver certification within a Bronze-Silver-Gold system. Sarin noted that initial skepticism turned into genuine interest as the workforce saw the leadership’s commitment backed by significant investment. “I believe people are truly adopting AI and focusing on their own skill development,” Sarin remarked.

Sarin believes the finance department plays a vital role in prioritization. With roughly 1,000 AI pilots currently active, she explained that the real value is captured when these trials are moved into production and integrated into standard workflows. Finance helps identify which pilots will have the most significant impact and deserve the resources to scale. “You have to identify which ones will truly make a difference,” she said.

AstraZeneca is currently investigating both generative and agentic AI as it develops the infrastructure needed to support a company that aims to be nearly twice its previous size if its growth targets are met.

AstraZeneca’s $80 billion strategy

AstraZeneca announced its $80 billion revenue goal for 2030 during an investor event in May 2024, at a time when analysts estimated revenue would be closer to $67 billion. Sarin admitted it was considered a very ambitious goal then, but leadership believed the company’s pipeline assets justified the target if their strategic bets were successful.

She outlined the progress toward this goal through three primary pillars. The first involves growing existing products in their approved uses across more than 80 global markets.

The second pillar is the expansion of current products into new indications—such as Imfinzi, which showed positive Phase 3 results this quarter for early-stage liver cancer, a use for which it is not yet approved. The third pillar focuses on entirely new molecular entities, with AstraZeneca aiming for 20 to be on the market by 2030. Currently, the company has nine, with FDA decisions pending for two additional medicines by the second quarter of 2026: camizestrant for breast cancer and baxdrostat for hypertension.

For the first quarter, AstraZeneca reported revenue of $15.29 billion, exceeding Wall Street forecasts by approximately $545 million. Operating profit rose by 12%, outperforming revenue growth despite continued investment in research and development. Sarin attributed the revenue success to strong momentum across the product line. While the cardiovascular and renal drug Farxiga performed well this quarter, its future performance will be affected by the loss of U.S. patent exclusivity on April 1 and its entry into China’s volume-based procurement program. AstraZeneca aims to have 25 blockbuster drugs—those earning over $1 billion annually—by 2030, up from its current 16.

When discussing how she handles macroeconomic and geopolitical challenges—such as tariffs and drug pricing policies—Sarin mentioned maintaining a calm and resilient approach. She viewed the last few years as a test of the company’s endurance, focusing on finding solutions and engaging with the policy environment rather than focusing on the problems. The company operates under the assumption that uncertainty is a constant, and success depends on how well-prepared a firm is to navigate it.

Sheryl Estrada
sheryl.estrada@.com